Exane Derivatives’s Metallus MTUS Stock Holding History

Exane Derivatives’s Portfolio MTUS Stock Details MTUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-14,643	Closed	-$197K	–	1081
2021 Q2	$197K	Buy	+14,643	New	+$198K	0.04%	397

Other funds holding MTUS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

SFM

Systematic Financial Management Teaneck, New Jersey $4.36B AUM 40.56% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Exane Derivatives's MTUS Position: Q3 2021 in Review

Exane Derivatives sold out of Metallus (MTUS) in Q3 2021, closing a stake of 14,643 shares — an estimated $197K sold.

Exane Derivatives first reported a position in MTUS in Q2 2021 and held it in 1 quarter. The position peaked at $197K in Q2 2021. 176 funds tracked by Wall St. Rank hold MTUS as of Q3 2021.

Exane Derivatives reported no remaining Metallus position as of Q3 2021 after selling out during the quarter.
Exane Derivatives sold 14,643 Metallus shares in Q3 2021, an estimated $197K.
Exane Derivatives first reported a position in Metallus in Q2 2021 and held it in 1 quarter.
Exane Derivatives's Metallus position peaked at $197K in Q2 2021.
176 funds tracked by Wall St. Rank held Metallus as of Q3 2021.

Based on Exane Derivatives's 13F filing for Q3 2021, filed 26 Oct 2021.